Lupus Nephritis

Severe Renal Arteriosclerosis in Lupus Nephritis Predicts ASCVD

Publish Date January 15, 2021

Severe renal arteriosclerosis in diagnostic lupus nephritis biopsies is associated with 9-fold higher odds of atherosclerotic cardiovascular disease.

Study Finds Clues to Rapid Progression to ESKD in Lupus Nephritis

Publish Date January 7, 2021

A small study suggests that poor medication compliance and certain histopathologic features may be associated with development of end-stage kidney disease within 3 years of lupus nephritis diagnosis.

Belimumab Approved for Active Lupus Nephritis in Adults

Publish Date December 22, 2020

In a randomized trial, belimumab (Benlysta) vs placebo added to standard therapy demonstrated superiority in achieving the primary efficacy renal response at 104 weeks.

Mycophenolate Mofetil vs Cyclophosphamide in the Induction Treatment of Lupus Nephritis

Publish Date November 4, 2020

Researchers evaluated the efficacy and safety of the induction treatment with mycophenolate mofetil and cyclophosphamide for lupus nephritis.

Low Platelet Distribution Width May Predict Lupus Nephritis

Publish Date August 28, 2020

Patients with systematic lupus erythematosus who have a low platelet distribution width (PDW) are more likely to have lupus nephritis than those with a normal or high PDW, a study found.

Voclosporin Granted Priority Review for Lupus Nephritis

Publish Date July 27, 2020

The FDA will give Priority Review to the New Drug Application (NDA) of voclosporin (Aurinia Pharmaceuticals) for the treatment of lupus nephritis.

Lack of EULAR/ERA-EDTA Response Predicts Chronic Kidney Disease in Patients With Lupus Nephritis

Publish Date June 24, 2020

Researchers evaluated EULAR/ERA-EDTA response to therapy in patients with lupus nephritis.

Belimumab Plus Standard Lupus Nephritis Therapy Improves Renal Responses

Publish Date June 9, 2020

Patients with LN who received belimumab in addition to standard therapy experienced a significant 49% decreased risk of renal-related events or death compared with those who received placebo plus standard therapy, a phase 3 study found.

Voclosporin NDA for Lupus Nephritis Submitted to FDA

Publish Date May 28, 2020

The New Drug Application (NDA) for voclosporin (Aurinia Pharmaceuticals) has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.

Updated EULAR/ERA-EDTA Recommendations for the Management of Lupus Nephritis

Publish Date May 5, 2020

The EULAR/ERA-EDTA developed updated recommendations for the management of lupus nephritis.